Zenas BioPharma, Inc.: stock overview

ZBIONASDAQHealthcare · Pharmaceutical Preparations

Price

$23.85

November 20, 2026Market cap $1.6B

What Ploutos Investor adds for Zenas BioPharma

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

In short

Zenas BioPharma had revenue of $11M over the last 12 months and a net loss of $542M. Revenue fell by 55.3% a year on average over the last 2 years. It holds more cash than debt, by $424M. It pays no dividend.

From its SEC filings (latest fiscal year to December 31, 2025) and the price of November 20, 2026.

Its SEC filings
Market cap
$1.6B
67.82M shares
P/E
–
Revenue, 12 months
$11M
-55.3% a year over 2 years
Net margin
-4,925.5%

Worth knowing

What a holder would want to hear from the company's SEC filings of the last three years. Each with its filing, without comment.

3 fiscal years in figures

Each fiscal year's figures as the company filed them, and the share price at its end.

2023–2025 fiscal years

-55.3% a year over 2 years

  • 202510-K
    Revenue$10M
  • 202410-K
    Revenue$5.0M
  • 2023
    Revenue$50M

Key figures

The company's current figures in five groups. Each term is explained behind its ⓘ.

Valuation

Market cap 
$1.6B
Enterprise value 
$1.2B
P/E 
–
EV / EBIT 
–
EV / Revenue 
108.5
P/B 
7.6
FCF yield 
–
Earnings yield 
–

Profitability

Operating margin 
-4,785.5%
Net margin 3-year median: -3,139.8%
-4,925.5%
ROIC 
-102.7%
ROIC, 5-year average 
-67.9%
ROE 
-219.6%

Growth

Revenue, yearly change 
+100.0%
EPS, yearly change 
–
FCF, yearly change 
–
Revenue, average a year 
-55.3%

The yearly change compares FY2025 with FY2024.

Balance sheet

Cash 
$647M
Total debt 
$225M
Of which operating leases 
$1.5M
Net cash 
$424M
Net debt / EBITDA 
–
Interest cover 
-71.8x
Current ratio 
9.42

Balance sheet of September 30, 2026.

Returns to shareholders

Dividend yield 
0.00%
Buybacks 
–
Total returned 
0.00%
Shares, yearly change 
+37.2%
Valuation against its own pastEach fiscal year's P/E, P/FCF and P/B beside today's, and the DCF calculator for the company.Valuation

The company at the SEC

How it is registered and when its fiscal year ends.

Name at the SEC
Zenas BioPharma, Inc.
Exchange
NASDAQ
Industry (SIC)
2834 · Pharmaceutical Preparations
Fiscal year ends
December 31
Latest annual report
December 31, 2025
Reporting currency
USD
Shares
67.82M

Other companies: Healthcare

The largest companies of the same sector, each with its own page.

The Healthcare sectorAll companies

The full analysis

What do Zenas BioPharma's filings show?

These are Zenas BioPharma's figures. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ZBIO

Didn't find what you were looking for?

Ask us
What is ZBIO's market cap?

Zenas BioPharma, Inc.'s market cap is $1.6B, at a price of $23.85 on November 20, 2026 and 67.82M shares.

How much revenue does ZBIO have?

Zenas BioPharma had revenue of $11M over the last 12 months. Over the last 2 years it changed by -55.3% a year on average.

Does ZBIO pay a dividend?

No. Zenas BioPharma paid no regular dividend over the last 12 months.

Where do the figures come from?

From Zenas BioPharma, Inc.'s SEC filings (10-K and 10-Q) and the share price. They hold no analyst estimates and no score, and they are not a recommendation.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.